Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
36.34
+0.01 (0.03%)
Oct 22, 2026, 4:00 PM EDT - Market closed

Pacira BioSciences Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Pacira BioSciences stock has a consensus rating of "Hold" and an average price target of $33.57. The average 1-year stock price forecast is 7.62% lower than the current stock price, while the lowest is $25 (-31.21%) and the highest is $36.5 (+0.44%).

Price Target: $33.57 (-7.62%)
Analyst Consensus: Hold

Price Target

Chart
TargetLowAverageMedianHigh
Price$25$33.57$36.5$36.5
Change-31.21%-7.62%+0.44%+0.44%

Analyst Ratings

The average analyst rating for Pacira BioSciences stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Chart
RatingMay '26Jun '26Jul '26Aug '26Sep '26Oct '26
Strong Buy322341
Buy111110
Hold222238
Sell111110
Strong Sell000000
Total766799

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
J.P. Morgan
J.P. Morgan
Hold
Upgrades
$23 → $37
HoldUpgrades$23 → $37+0.44%Oct 13, 2026
Leerink Partners
Leerink Partners
Hold
Reiterates
$28 → $37
HoldReiterates$28 → $37+0.44%Oct 9, 2026
RBC Capital
RBC Capital
Hold
Reiterates
$25 → $37
HoldReiterates$25 → $37+0.44%Oct 9, 2026
H.C. Wainwright
H.C. Wainwright
Hold
Downgrades
$38 → $37
HoldDowngrades$38 → $37+0.44%Oct 9, 2026
Oppenheimer
Oppenheimer
Hold
Downgrades
n/a
HoldDowngradesn/an/aOct 8, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
754.33M
from 726.41M
Increased by 3.84%
Revenue Next Year
790.02M
from 754.33M
Increased by 4.73%
EPS This Year
2.90
from 2.65
Increased by 9.28%
EPS Next Year
3.46
from 2.90
Increased by 19.44%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
541.53M666.82M674.98M700.97M726.41M754.33M
Revenue Growth
26.04%23.14%1.22%3.85%3.63%3.84%
Gross Profit
401.28M467.53M490.31M530.54M576.66M592.30M
Gross Margin
74.10%70.11%72.64%75.69%79.39%78.52%
Operating Income
89.92M70.93M87.32M97.57M33.30M156.30M
Net Income
41.98M15.91M41.96M-99.56M7.03M28.95M
EPS
----2.652.90
EPS Growth
-----17.19%9.28%
Forward PE
15.4311.6410.237.107.5312.55
Free Cash Flow
----136.66M183.37M
No. Analysts
-----8
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High759.4M
Avg754.3M
Low747.8M

Revenue Growth

Revenue Growth202620272028
High
4.5%
Avg
3.8%
Low
2.9%

EPS Forecast

EPS202620272028
High2.99
Avg2.90
Low2.72

EPS Growth

EPS Growth202620272028
High
12.8%
Avg
9.3%
Low
2.5%